Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia

Experimental Hematology

Volumn 37, Issue 6, 2009, Pages 679-691

  Barbarroja, Nuria ^a   Torres, Luis Arístides ^a   Luque, Maria Jose ^a   Carretero, Rosario Maria ^a   Valverde Estepa, Araceli ^a   Lopez Sanchez, Laura Maria ^a   Rodriguez Ariza, Antonio ^a   Velasco, Francisco ^a   Torres, Antonio ^a   López Pedrera, Chary ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; IDARUBICIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; MONOTHERAPY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; DRUG SYNERGISM; FMS-LIKE TYROSINE KINASE 3; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549097160     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.03.001     Document Type: Article

References (48)

1. Padro T., Ruiz S., Bieker R., et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 96 (2000) 2637-2644
2. Hussong J.W., Rodgers G.M., and Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95 (2000) 309-313
3. de Bont E.S., Rosati S., Jacobs S., Kamps W.A., and Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113 (2001) 296-304
4. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
5. Aguayo A., Estey E., Kantarjian H., et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 94 (1999) 3717-3721
6. Fragoso R., Elias A.P., and Dias S. Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma 48 (2007) 481-488
7. Dias S., Hattori K., Heissig B., et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci U S A 98 (2001) 10857-10862
8. Padro T., Bieker R., Ruiz S., et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16 (2002) 1302-1310
9. Weber-Nordt R.M., Mertelsmann R., and Finke J. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma 28 (1998) 459-467
10. Grandage V.L., Gale R.E., Linch D.C., and Kchwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB. Mapkinase and p53 pathways. Leukemia 19 (2005) 586-594
11. Lewis T.S., Shapiro P.S., and Ahn N.G. Signal transduction through MAP kinase cascades. Adv Cancer Res 74 (1998) 49-139
12. Kainz B., Fonatsch C., Schwarzinger I., Sperr W.R., Jäger U., and Gaiger A. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia. Haematologica 90 (2005) 695-696
13. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (2001) 1752-1759
14. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99 (2002) 4326-4335
15. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
16. O'Farrell A.M., Yuen H.A., Smolich B., et al. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leukemia Res 28 (2004) 679-689
17. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
18. Drevs J., Muller-Driver R., Wittig C., et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62 (2002) 4015-4022
19. Hess-Stumpp H., Haberey M., and Thierauch K.H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 6 (2005) 550-557
20. Giles F.J., Stopeck A.T., Silverman L.R., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102 (2003) 795-801
21. Fiedler W., Mesters R., Tinnefeld H., et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (2003) 2763-2767
22. Roboz G.J., Giles F.J., List A.F., et al. Phase I study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 6 (2006) 952-957
23. Weidenaar A.C., de Jonge H.J., Fidler V., et al. Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anticancer Drugs 19 (2008) 45-54
24. Srinivasa S.P., and Doshi P.D. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 16 (2002) 244-253
25. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
26. Kubota Y., Ohnishi H., Kitanaka A., Ishida T., and Tanaka T. Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18 (2004) 1438-1440
27. Xia Z., Baer M.R., Block A.W., Baumann H., and Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 58 (1998) 3173-3180
28. Barbarroja N., Torres L.A., Hernandez V., et al. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leuk Lymphoma 48 (2007) 1187-1199
29. Siendones E., Barbarroja N., Torres L.A., et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25 (2007) 30-37
30. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N Engl J Med 341 (1999) 1051-1062
31. Kimby E., Nygren P., and Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 40 (2001) 231-252
32. Estey H. Therapeutic options for acute myelogenous leukemia. Cancer 92 (2001) 1059-1073
33. Bellamy W., Richter L., Sirjani D., et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 97 (2001) 1427-1434
34. Joensuu H., De Braud F., Coco P., et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19 (2008) 173-177
35. George D., Jonasch E., Hart L., et al. A phase I, dose escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas. Clin Cancer Res 7 (2001) 548a
36. George D., Michaelson D., Oh W.K., et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22 (2003) 385 Abstract 1548
37. Friedman H.S., Yung W.A., Jackson E., et al. A phase I trial of PTK787/ZK222584 (PTK/ZK), a novel oral VEGF-R TK inhibitor in patients with recurrent GBM. Clin Cancer Res 7 (2001) 58a
38. Dias S., Hattori K., Zhu Z., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106 (2000) 511-521
39. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with a potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
40. Scholl C., Gilliland D.G., and Fröhling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 35 (2008) 336-345
41. Doepfner K.T., Boller D., and Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 63 (2007) 215-230
42. List A.F., Glinsmann-Gibson B., Stadheim C., Meuillet E.J., Bellamy W., and Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 32 (2004) 526-535
43. Spierkermann K., Bagrintseva K., Schwab R., Schieja K., and Hiddemann W. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin Cancer Res 9 (2003) 2140-2150
44. Choudhary C., Brandts C., Schwable J., et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 110 (2007) 370-374
45. Brandts C.H., Sargin B., Rode M., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65 (2005) 9643-9650
46. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
47. Gasparini G., Longo R., Fanelli M., and Teicher B.A. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges and open questions. J Clin Oncol 23 (2005) 1295-1311
48. Creutzig U., Körholz D., Niemeyer C.M., et al. Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children. Klin Padiatr 212 (2000) 163-168